Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs
ConclusionThe French EA reform contributed to enabling rapid access to innovations in a wide range of indications for oncology patients. However, the findings highlight ongoing challenges in financial sustainability, warranting continued evaluation and adjustments.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Drugs & Pharmacology | France Health | Hematology | Study